Dergiler / Turkish Journal of Pediatrics / 2016 / Cilt: 58 - Sayı: 3

Serum IL-13 levels at diagnosis and remission in children with malignant lymphoma

Sayfa
246–253
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The median serum IL-13 level at diagnosis (range 0.59-68 pg/ml, median 3.40 pg/ml) was higher than that in remission (range 0.14-12.2 pg/ml, median 1.60 pg/ml) in the HL group (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:ÖzyörükD, Yavuz G, Dinçaslan H, Cabı-Unal E, TaçyıldızN, Karataş D, Doğu F, İkincioğulları A.
📊
Temel Bulgular & Veri:Serum IL-13 levels at diagnosis and remission in children with malignant lymphoma.
💡
Sonuç & Katkı:The median serum IL-13 level at diagnosis (range 0.59-68 pg/ml, median 3.40 pg/ml) was higher than that in remission (range 0.14-12.2 pg/ml, median 1.60 pg/ml) in the HL group (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

ÖzyörükD, Yavuz G, Dinçaslan H, Cabı-Unal E, TaçyıldızN, Karataş D, Doğu F, İkincioğulları A. Serum IL-13 levels at diagnosis and remission in children with malignant lymphoma. Turk J Pediatr 2016; 58: 246-253.Interleukin (IL)-13 has been reported to have a role in the pathogenesis of lymphoma through recent molecular studies predominantly in adult patients. As malignant lymphomas in children differ from adult counterparts in terms of histology and response to treatment, we aimed to determine the serum IL-13 levels of patients with lymphoma; its relation with clinical-laboratory parameters and to look for any correlation of serum IL-13 levels with different prognostic factors in children. Twenty-eight patients with malignant lymphoma and 20 age-matched healthy controls were included in the study. The median serum IL-13 level at diagnosis (range 0.59-68 pg/ml, median 3.40 pg/ml) was higher than that in remission (range 0.14-12.2 pg/ml, median 1.60 pg/ml) in the HL group (p

🔖

Bu Makaleye Atıf Yap

ÖZYÖRÜK, D., DOĞU, F., KARATAŞ, D., TAÇYILDIZ, N., İKİNCİOĞULLARI, A., CABI-UNAL, E., YAVUZ, G., DİNÇASLAN, H. (2022). Serum IL-13 levels at diagnosis and remission in children with malignant lymphoma. Turkish Journal of Pediatrics, Cilt: 58 - Sayı: 3, 246–253. https://ajindex.com/articles/654521

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Hudson MM. Hodgkin lymphoma. In: Principles and Practice of Pediatric Oncology. Philadelphia: Lipincott Williams and Wilkins; 2006: 695-721
  2. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001: 38: 368-375
  3. Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999: 189:1939- 1946
  4. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001: 97: 250-255
  5. Defrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. J Exp Med 1994: 179:135-143
  6. McKenzie AN, Culpepper JA, de Waal Malefyt R, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci U S A 1993: 90: 3735-3739
  7. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-456
  8. Fiumara P, Cabanillas F, Younes A. Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. Blood 2001: 98: 2877-2878
  9. Alexander S, Ferrando AA. Pediatric lymphoma. Nathan and Oski's Hematology and Oncology of Infancy and Childhood. Eight ed. Vol 2:1626-1672
  10. Lanzkowsky P. Hodgkin Disease. In: Manual of Pediatric Hematology and Oncology. (4th ed). San Diego: Elsevier Academic Press, 2005: 453-490
  11. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002; 43:1203-1210
  12. Skinnider BF, Kapp U, Mak TW. Interleukin 13: a growth factor in hodgkin lymphoma. Int Arch Allergy Immunol 2001; 126: 267-276
  13. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002: 99: 4283-4297
  14. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99: 618-626
  15. Gaiolla RD, Domingues MA, Niero-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med 2011; 135: 483-489
  16. Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011; 2011: 317-322
  17. Schellong G, Potter R